Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 265

1.

HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy.

Emmons MF, Faião-Flores F, Sharma R, Thapa R, Messina JL, Becker JC, Schadendorf D, Seto E, Sondak VK, Koomen JM, Chen YA, Lau EK, Wan L, Licht JD, Smalley KSM.

Cancer Res. 2019 Apr 15. pii: canres.0040.2019. doi: 10.1158/0008-5472.CAN-19-0040. [Epub ahead of print]

PMID:
30987999
2.

Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.

Alzrigat M, Jernberg-Wiklund H, Licht JD.

Epigenomes. 2018 Sep;2(3). pii: 16. doi: 10.3390/epigenomes2030016. Epub 2018 Sep 3.

3.

Inhibition of cardiomyocyte Sprouty1 protects from cardiac ischemia-reperfusion injury.

Alakoski T, Ulvila J, Yrjölä R, Vainio L, Magga J, Szabo Z, Licht JD, Kerkelä R.

Basic Res Cardiol. 2019 Jan 11;114(2):7. doi: 10.1007/s00395-018-0713-y.

4.

Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.

Kim J, Lee Y, Lu X, Song B, Fong KW, Cao Q, Licht JD, Zhao JC, Yu J.

Cell Rep. 2018 Dec 4;25(10):2808-2820.e4. doi: 10.1016/j.celrep.2018.11.035.

5.

An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.

Swaroop A, Oyer JA, Will CM, Huang X, Yu W, Troche C, Bulic M, Durham BH, Wen QJ, Crispino JD, MacKerell AD Jr, Bennett RL, Kelleher NL, Licht JD.

Oncogene. 2019 Jan;38(5):671-686. doi: 10.1038/s41388-018-0474-y. Epub 2018 Aug 31.

6.
7.

USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.

Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, Gao B, Montauti E, Kirsammer G, Licht JD, Yu J, Ji P, Crispino JD, Fang D.

Blood. 2018 Jul 26;132(4):423-434. doi: 10.1182/blood-2017-10-811760. Epub 2018 May 29.

8.

CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia.

Luo H, Wang F, Zha J, Li H, Yan B, Du Q, Yang F, Sobh A, Vulpe C, Drusbosky L, Cogle C, Chepelev I, Xu B, Nimer SD, Licht J, Qiu Y, Chen B, Xu M, Huang S.

Blood. 2018 Aug 23;132(8):837-848. doi: 10.1182/blood-2017-11-814319. Epub 2018 May 14.

9.

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.

Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, Scheltens P, Schmidt ME, Streffer J, Novak G, Einstein S, Booth K, Ketter N, Brashear HR; ELN115727-301/302 Investigator Group.

Neurology. 2018 Mar 6;90(10):e877-e886. doi: 10.1212/WNL.0000000000005060. Epub 2018 Feb 2.

PMID:
29429971
10.

A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer.

Fantini D, Glaser AP, Rimar KJ, Wang Y, Schipma M, Varghese N, Rademaker A, Behdad A, Yellapa A, Yu Y, Sze CC, Wang L, Zhao Z, Crawford SE, Hu D, Licht JD, Collings CK, Bartom E, Theodorescu D, Shilatifard A, Meeks JJ.

Oncogene. 2018 Apr;37(14):1911-1925. doi: 10.1038/s41388-017-0099-6. Epub 2018 Jan 25.

11.

SETD2: a complex role in blood malignancy.

Licht JD.

Blood. 2017 Dec 14;130(24):2576-2578. doi: 10.1182/blood-2017-10-811927. No abstract available.

12.

Loss of Spry1 attenuates vascular smooth muscle proliferation by impairing mitogen-mediated changes in cell cycle regulatory circuits.

Yang X, Gong Y, He Q, Licht JD, Liaw L, Friesel RE.

J Cell Biochem. 2018 Apr;119(4):3267-3279. doi: 10.1002/jcb.26486. Epub 2017 Dec 26.

13.

UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.

Ezponda T, Dupéré-Richer D, Will CM, Small EC, Varghese N, Patel T, Nabet B, Popovic R, Oyer J, Bulic M, Zheng Y, Huang X, Shah MY, Maji S, Riva A, Occhionorelli M, Tonon G, Kelleher N, Keats J, Licht JD.

Cell Rep. 2017 Oct 17;21(3):628-640. doi: 10.1016/j.celrep.2017.09.078.

14.

Targeting Epigenetics in Cancer.

Bennett RL, Licht JD.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:187-207. doi: 10.1146/annurev-pharmtox-010716-105106. Epub 2017 Oct 6.

15.

JNK Activation Turns on LPS- and Gram-Negative Bacteria-Induced NADPH Oxidase-Dependent Suicidal NETosis.

Khan MA, Farahvash A, Douda DN, Licht JC, Grasemann H, Sweezey N, Palaniyar N.

Sci Rep. 2017 Jun 13;7(1):3409. doi: 10.1038/s41598-017-03257-z.

16.

The nucleus is irreversibly shaped by motion of cell boundaries in cancer and non-cancer cells.

Tocco VJ, Li Y, Christopher KG, Matthews JH, Aggarwal V, Paschall L, Luesch H, Licht JD, Dickinson RB, Lele TP.

J Cell Physiol. 2018 Feb;233(2):1446-1454. doi: 10.1002/jcp.26031. Epub 2017 Jul 31.

17.

Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.

Dupéré-Richer D, Licht JD.

Curr Opin Hematol. 2017 Jul;24(4):336-344. doi: 10.1097/MOH.0000000000000358. Review.

18.

The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

Bennett RL, Swaroop A, Troche C, Licht JD.

Cold Spring Harb Perspect Med. 2017 Jun 1;7(6). pii: a026708. doi: 10.1101/cshperspect.a026708. Review.

19.

FQI1: a transcription-methylation switch for cancer.

Guryanova OA, Licht JD.

Oncotarget. 2017 Feb 21;8(8):12536-12537. doi: 10.18632/oncotarget.15087. No abstract available.

20.

Sabotaging of the oxidative stress response by an oncogenic noncoding RNA.

Mahajan N, Wu HJ, Bennett RL, Troche C, Licht JD, Weber JD, Maggi LB Jr, Tomasson MH.

FASEB J. 2017 Feb;31(2):482-490. doi: 10.1096/fj.201600654R. Epub 2016 Oct 24.

Supplemental Content

Loading ...
Support Center